{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:41:05Z","timestamp":1762454465769,"version":"build-2065373602"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Catatonia is a rare but potentially life-threatening psycho-motor syndrome. It is mainly manifested as decreased activities, or excessive and specific activities, such as stupor, agitation and defiance. Catatonia can appear in various diseases and the diagnosis and treatment of depressive catatonia are often delayed. As an N-methyl-D-aspartate (NMDA) receptor antagonist, esketamine shows antidepressant and anti-catatonic effects by regulating glutamatergic signal transduction and enhancing synaptic plasticity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The present case involved a 55-year-old woman with depressive catatonia. Benzodiazepines, aripiprazole and nutritional support were given after admission. As she had a poor response to the initial treatment, we considered using the modified electroconvulsive therapy (MECT). Due to the deep vein thrombosis in the lower extremities, the application of MECT was restricted. With the consent of her and family, we decied to administrate a sub-anesthetic dose of intravenous (IV) Esketamine (0.2 mg\/Kg) combined with 50mg desvenlafaxine. During the process, we assessed the effect by comparing depression severity scores using validated psychiatric scales before and after the treatment. Adverse drug reactions were evaluated by adverse drug reaction scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>The symptoms of catatonia were relieved in 4 hours after esketamine administration. The Bush-Francis Catatonia Rating Scale (BFCRS) decreased from 19 to 0. 48 hours after injection, the depressive symptoms were relieved and the Montgomery \u00c5sberg Depression Rating Scale (MADRS) decreased from 46 to 9. The condition remained stable on 20 weeks of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>As a safe and rapid intervention, Esketamine might be a new option for catatonic patients who cannot undergo MECT or fail to respond to conventional treatment. It may be worthy of further research in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1688633","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:36:55Z","timestamp":1762454215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose intravenous esketamine on a depressive catatonia patient with venous thromboembolism: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Meng-han","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.7861\/clinmed.2023-0113","article-title":"The diagnosis and treatment of catatonia","volume":"23","author":"Rogers","year":"2023","journal-title":"Clin Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/08850666221114303","article-title":"Malignant catatonia: A review for the intensivist","volume":"38","author":"Connell","year":"2023","journal-title":"J Intensive Care Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/bdi.12348","article-title":"Catatonia in 26 patients with bipolar disorder: clinical features and response to electroconvulsive therapy","volume":"17","author":"Medda","year":"2015","journal-title":"Bipolar Disord"},{"key":"B4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/YCT.0b013e3181c18a13","article-title":"Electroconvulsive therapy for catatonia: treatment characteristics and outcomes in 27 patients","volume":"26","author":"Van Waarde","year":"2010","journal-title":"J ECT"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2190\/X0FF-VU7G-QQP7-L5V7","article-title":"Somatic Treatment of Catatonia","volume":"25","author":"Hawkins","year":"1995","journal-title":"Int J Psychiatry Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1996.tb09815.x","article-title":"Catatonia. II. Treatment with lorazepam and electroconvulsive therapy","volume":"93","author":"Bush","year":"1996","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.2009.21.4.371","article-title":"Catatonia: clinical aspects and neurobiological correlates","volume":"21","author":"Daniels","year":"2009","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41572-024-00534-w","article-title":"Catatonia","volume":"10","author":"Hirjak","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2024.09.005","article-title":"N-methyl-d-aspartate (NMDA) receptor antagonists for treatment of catatonia in adults: Narrative review","volume":"91","author":"Lee","year":"2024","journal-title":"Gen Hosp Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2024.07.055","article-title":"Ketamine for catatonia: A novel treatment for an old clinical challenge? A systematic review of the evidence","volume":"271","author":"Caliman-Fontes","year":"2024","journal-title":"Schizophr Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231158232","article-title":"Evidence-based consensus guidelines for the management of catatonia: recommendations from the British association for psychopharmacology","volume":"37","author":"Rogers","year":"2023","journal-title":"J Psychopharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2018.04.001","article-title":"The probability that catatonia in the hospital has a medical cause and the relative proportions of its causes: A systematic review","volume":"59","author":"Oldham","year":"2018","journal-title":"Psychosomatics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/YCT.0000000000000433","article-title":"The use of lorazepam and electroconvulsive therapy in the treatment of catatonia: treatment characteristics and outcomes in 60 patients","volume":"33","author":"Unal","year":"2017","journal-title":"J ECT"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S231573","article-title":"Electroconvulsive therapy for patients with catatonia: current perspectives","volume":"16","author":"Lloyd","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1176\/jnp.2007.19.4.406","article-title":"Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes","volume":"19","author":"Carroll","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12902","article-title":"Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective","volume":"73","author":"Hashimoto","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2023.2028","article-title":"Intranasal esketamine administration in catatonia: A case report","volume":"66","author":"Romay","year":"2023","journal-title":"Eur Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2023.01.003","article-title":"K\u00e9tamine et loraz\u00e9pam: un traitement de la d\u00e9pression catatonique du sujet \u00e2g\u00e9","volume":"49","author":"Laurin","year":"2023","journal-title":"L\u2019Enc\u00e9phale"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1688633\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:36:56Z","timestamp":1762454216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1688633\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":18,"alternative-id":["10.3389\/fpsyt.2025.1688633"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1688633","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1688633"}}